OBJECTIVE: The objective of this study was to describe clinical features, [18 F]-fluorodeoxyglucose (FDG)-positron emission tomography (PET) metabolism and digital pathology in patients with logopenic progressive aphasia (LPA) and pathologic diagnosis of diffuse Lewy body disease (DLBD) and compare to patients with LPA with other pathologies, as well as patients with classical features of probable dementia with Lewy bodies (pDLB). METHODS: This is a clinicopathologic case-control study of 45 patients, including 20 prospectively recruited patients with LPA among whom 6 were diagnosed with LPA-DLBD. We analyzed clinical features and compared FDG-PET metabolism in LPA-DLBD to an independent group of patients with clinical pDLB and regional α-synuclein burden on digital pathology to a second independent group of autopsied patients with DLBD pathology and antemortem pDLB (DLB-DLBD). RESULTS: All patients with LPA-DLBD were men. Neurological, speech, and neuropsychological characteristics were similar across LPA-DLBD, LPA-Alzheimer's disease (LPA-AD), and LPA-frontotemporal lobar degeneration (LPA-FTLD). Genetic screening of AD, DLBD, and FTLD linked genes were negative with the exception of APOE ε4 allele present in 83% of LPA-DLBD patients. Seventy-five percent of the patients with LPA-DLBD showed a parietal-dominant pattern of hy pometabolism; LPA-FTLD - temporal-dominant pattern, whereas LPA-AD showed heterogeneous patterns of hypometabolism. LPA-DLBD had more asymmetrical hypometabolism affecting frontal lobes, with relatively spared occipital lobe in the nondominantly affected hemisphere, compared to pDLB. LPA-DLBD had minimal atrophy on gross brain examination, higher cortical Lewy body counts, and higher α-synuclein burden in the middle frontal and inferior parietal cortices compared to DLB-DLBD. INTERPRETATION: Whereas AD is the most frequent underlying pathology of LPA, DLBD can also be present and may contribute to the LPA phenotype possibly due to α-synuclein-associated functional impairment of the dominant parietal lobe. ANN NEUROL 2021;89:520-533.
OBJECTIVE: The objective of this study was to describe clinical features, [18 F]-fluorodeoxyglucose (FDG)-positron emission tomography (PET) metabolism and digital pathology in patients with logopenic progressive aphasia (LPA) and pathologic diagnosis of diffuse Lewy body disease (DLBD) and compare to patients with LPA with other pathologies, as well as patients with classical features of probable dementia with Lewy bodies (pDLB). METHODS: This is a clinicopathologic case-control study of 45 patients, including 20 prospectively recruited patients with LPA among whom 6 were diagnosed with LPA-DLBD. We analyzed clinical features and compared FDG-PET metabolism in LPA-DLBD to an independent group of patients with clinical pDLB and regional α-synuclein burden on digital pathology to a second independent group of autopsied patients with DLBD pathology and antemortem pDLB (DLB-DLBD). RESULTS: All patients with LPA-DLBD were men. Neurological, speech, and neuropsychological characteristics were similar across LPA-DLBD, LPA-Alzheimer's disease (LPA-AD), and LPA-frontotemporal lobar degeneration (LPA-FTLD). Genetic screening of AD, DLBD, and FTLD linked genes were negative with the exception of APOE ε4 allele present in 83% of LPA-DLBD patients. Seventy-five percent of the patients with LPA-DLBD showed a parietal-dominant pattern of hy pometabolism; LPA-FTLD - temporal-dominant pattern, whereas LPA-AD showed heterogeneous patterns of hypometabolism. LPA-DLBD had more asymmetrical hypometabolism affecting frontal lobes, with relatively spared occipital lobe in the nondominantly affected hemisphere, compared to pDLB. LPA-DLBD had minimal atrophy on gross brain examination, higher cortical Lewy body counts, and higher α-synuclein burden in the middle frontal and inferior parietal cortices compared to DLB-DLBD. INTERPRETATION: Whereas AD is the most frequent underlying pathology of LPA, DLBD can also be present and may contribute to the LPA phenotype possibly due to α-synuclein-associated functional impairment of the dominant parietal lobe. ANN NEUROL 2021;89:520-533.
Authors: Bradley T Hyman; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Maria C Carrillo; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; Bill Thies; John Q Trojanowski; Harry V Vinters; Thomas J Montine Journal: Alzheimers Dement Date: 2012-01 Impact factor: 21.566
Authors: S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg Journal: Neurology Date: 1991-04 Impact factor: 9.910
Authors: Richard A Goodman; Kimberly A Lochner; Madhav Thambisetty; Thomas S Wingo; Samuel F Posner; Shari M Ling Journal: Alzheimers Dement Date: 2016-05-10 Impact factor: 21.566
Authors: Kamini Krishnan; Mary M Machulda; Jennifer L Whitwell; Alissa M Butts; Joseph R Duffy; Edythe A Strand; Matthew L Senjem; Anthony J Spychalla; Clifford R Jack; Val J Lowe; Keith A Josephs Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: K A Josephs; J L Whitwell; J R Duffy; W A Vanvoorst; E A Strand; W T Hu; B F Boeve; N R Graff-Radford; J E Parisi; D S Knopman; D W Dickson; C R Jack; R C Petersen Journal: Neurology Date: 2008-01-01 Impact factor: 9.910
Authors: Samuel Boes; Hugo Botha; Mary Machulda; Val Lowe; Jonathan Graff-Radford; Jennifer L Whitwell; Rene L Utianski; Joseph R Duffy; Keith A Josephs Journal: Neurocase Date: 2020-07-16 Impact factor: 0.881
Authors: Ian R A Mackenzie; Manuela Neumann; Atik Baborie; Deepak M Sampathu; Daniel Du Plessis; Evelyn Jaros; Robert H Perry; John Q Trojanowski; David M A Mann; Virginia M Y Lee Journal: Acta Neuropathol Date: 2011-06-05 Impact factor: 17.088
Authors: Alan J Thomas; Johannes Attems; Sean J Colloby; John T O'Brien; Ian McKeith; Rodney Walker; Lean Lee; David Burn; Debra J Lett; Zuzana Walker Journal: Neurology Date: 2016-12-09 Impact factor: 9.910
Authors: Clifford R Jack; Heather J Wiste; Hugo Botha; Stephen D Weigand; Terry M Therneau; David S Knopman; Jonathan Graff-Radford; David T Jones; Tanis J Ferman; Bradley F Boeve; Kejal Kantarci; Val J Lowe; Prashanthi Vemuri; Michelle M Mielke; Julie A Fields; Mary M Machulda; Christopher G Schwarz; Matthew L Senjem; Jeffrey L Gunter; Ronald C Petersen Journal: Brain Date: 2019-10-01 Impact factor: 13.501
Authors: Neha Atulkumar Singh; Jonathan Graff-Radford; Mary M Machulda; Christopher G Schwarz; Matthew C Baker; Rosa Rademakers; Nilufer Ertekin-Taner; Val J Lowe; Keith A Josephs; Jennifer L Whitwell Journal: J Neurol Date: 2022-08-24 Impact factor: 6.682
Authors: Jennifer L Whitwell; Nirubol Tosakulwong; Stephen D Weigand; Jonathan Graff-Radford; Nilufer Ertekin-Taner; Mary M Machulda; Joseph R Duffy; Christopher G Schwarz; Matthew L Senjem; Clifford R Jack; Val J Lowe; Keith A Josephs Journal: Neurobiol Aging Date: 2021-08-25 Impact factor: 5.133
Authors: Jennifer Whitwell; Peter R Martin; Jonathan Graff-Radford; Mary Machulda; Irene Sintini; Marina Buciuc; Matthew L Senjem; Christopher G Schwarz; Hugo Botha; Minerva M Carrasquillo; Nilufer Ertekin-Taner; Val J Lowe; Clifford R Jack; Keith Anthony Josephs Journal: Neurology Date: 2022-04-28 Impact factor: 11.800
Authors: Changiz Geula; Sara R Dunlop; Ivan Ayala; Allegra S Kawles; Margaret E Flanagan; Tamar Gefen; Marek-Marsel Mesulam Journal: J Neurochem Date: 2021-08-06 Impact factor: 5.546